Myriad Genetics Names Ben Wheeler as New CFO
ByAinvest
Monday, Aug 18, 2025 5:03 pm ET1min read
MYGN--
The outgoing CFO, Scott Leffler, who has been in the role since January 2024, will transition to a consulting role serving the CEO and the Board of Directors through September 2, 2025 [1]. Leffler's departure is part of a broader executive reshuffle aimed at streamlining operations and aligning the company's financial strategy with its long-term growth objectives.
Wheeler's extensive tenure with Myriad and his proven track record in financial leadership positions him to lead the company's finance team effectively. "I'm excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad's mission and long-term growth strategy," said Mr. Wheeler [1].
The company has reaffirmed its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025 [1]. This guidance reflects Myriad's commitment to maintaining its profitable growth trajectory despite the ongoing challenges in the healthcare sector.
Myriad Genetics is dedicated to developing and offering molecular tests that assess the risk of developing disease or disease progression and guide treatment decisions across various medical specialties. The company's mission is to significantly improve patient care and lower healthcare costs through molecular insights [2].
References:
[1] https://investor.myriad.com/news-releases/news-release-detail/26586/
[2] https://www.nasdaq.com/articles/myriad-genetics-appoints-ben-wheeler-chief-financial-officer
Myriad Genetics has appointed Ben Wheeler as its new CFO, effective August 16, 2025. Wheeler has been with the company since 2011 and most recently served as CFO of Operations since 2022. Outgoing CFO Scott Leffler will move into a consulting role.
Myriad Genetics, Inc. (NASDAQ: MYGN), a leading molecular diagnostic testing and precision medicine company, has appointed Ben Wheeler as its new Chief Financial Officer (CFO), effective August 16, 2025. Wheeler has been with the company since 2011, holding various roles including assistant controller, vice president, corporate controller, senior vice president, accounting, and CFO, operations since 2022 [1].The outgoing CFO, Scott Leffler, who has been in the role since January 2024, will transition to a consulting role serving the CEO and the Board of Directors through September 2, 2025 [1]. Leffler's departure is part of a broader executive reshuffle aimed at streamlining operations and aligning the company's financial strategy with its long-term growth objectives.
Wheeler's extensive tenure with Myriad and his proven track record in financial leadership positions him to lead the company's finance team effectively. "I'm excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad's mission and long-term growth strategy," said Mr. Wheeler [1].
The company has reaffirmed its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025 [1]. This guidance reflects Myriad's commitment to maintaining its profitable growth trajectory despite the ongoing challenges in the healthcare sector.
Myriad Genetics is dedicated to developing and offering molecular tests that assess the risk of developing disease or disease progression and guide treatment decisions across various medical specialties. The company's mission is to significantly improve patient care and lower healthcare costs through molecular insights [2].
References:
[1] https://investor.myriad.com/news-releases/news-release-detail/26586/
[2] https://www.nasdaq.com/articles/myriad-genetics-appoints-ben-wheeler-chief-financial-officer
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet